David Sidransky, M.D., renowned oncologist and a consultant to a number of leading biotechnology companies, is the Director of the Head and Neck Cancer Research Division at Johns Hopkins University School of Medicine.  In addition, he is Professor of Oncology, Otolaryngology, Cellular & Molecular Medicine, Urology, Genetics, and Pathology at John Hopkins University and Hospital.  He has served as a director of Imclone since January 2004.  Dr. Sidransky is a founder of numerous biotechnology companies, and holds a number of biotechnology patents.  He is serving and has served on scientific advisory boards of many private and public companies, including MedImmune, Roche, Amgen and Veridex, LLC (a Johnson & Johnson diagnostic company).  Dr. Sidransky is Vice Chairman of Alfacell Inc., and serves as Director of the American Association of Cancer Research (AACR).  He has over 300 peer-reviewed publications, and has contributed more than 40 cancer reviews and chapters.  He is the recipient of many awards and honors, including the 1997 Sarstedt International prize from the German Society of Clinical Chemistry, the 1998 Alton Ochsner Award Relating Smoking and Health by the American College of Chest Physicians and the 2004 Hinda and Richard Rosenthal Award from the AACR.

Michael N. Liebman, Ph.D. is the Managing Director of Strategic Medicine, Inc and is also a Senior Institute Fellow at the Windber Research Institute after serving as its Executive Director since November, 2003.  Previously, he was Director of Computational Biology and Biomedical Informatics at the Abramson Family Cancer Research Institute of the University of Pennsylvania Cancer Center.  He served as Global Head of Computational Genomics at Roche Pharmaceuticals, and Director of Bioinformatics and Pharmacogenomics at Wyeth Pharmaceuticals.  In addition, he was Director of Genomics for Vysis, Inc. and Director of Bioinformatics at the Amoco Technology Company.  He has served on the faculty of Mount Sinai School of Medicine in Pharmacology and Physiology/Biophysics.   He serves on 12 international scientific advisory boards, consults for 5 pharma/biotech companies and has been on the economic development programs in the Philadelphia Life Sciences Sector and the State of Illinois Biotechnology Commission.  He is an Invited Professor at the Shanghai Center for Bioinformatics Technology and is currently Chair of the Healthcare Task Force for the SMART program, and is on the Human Health and Medicinal Chemistry Commission of the IUPAC.  His research focuses on computational models of disease progression stressing risk detection, disease process modeling and analysis of lifestyle interactions.

David M. Johnston, Ph.D., is Vice President and the Chief Scientific Officer for Esoterix Clinical Trials Services (Esoterix), the clinical trials division of LabCorp. Esoterix provides specialized and routine laboratory analyses for pharmaceutical and diagnostic product development worldwide. Dr. Johnston earned his Ph.D. in Microbiology and Immunology from the University of North Carolina at Chapel Hill School of Medicine and has been involved in clinical research for more than 15 years. Dr. Johnston studied gene regulation and surface virulence determinants in the pathogenic Neisseriae. He later studied drug resistance in HIV and worked on the first clinical diagnostic assays to detect HIV drug resistance mutations. Previously, Dr. Johnston held leadership positions in Research and Development and clinical trials Quality Assurance at LabCorp. Dr. Johnston participated in the DIA workshops on pharmacogenomics data submissions and served on the AACC Advisory Committee on pharmacogenomic assay validation. Dr. Johnston is an adjunct professor in the clinical research department of the Campbell University School of Pharmacy, and serves on the scientific advisory board for Kylin Therapeutics. He is a member of the American Association for the Advancement of Science, the Drug Information Association, American Association for Clinical Chemistry, and American Society for Microbiology.

James L. Mulshine M. D., noted oncologist at the National Cancer Institute (NCI) for twenty-five years, is now the Associate Provost for Research at Rush University Medical Center in Chicago.  He was previously Head of the Intervention Section, Cell and Cancer Biology Department, Division of Clinical Sciences for the NCI in Maryland.  After graduating from the Loyola Stritch School of Medicine in 1977, he completed a Fellowship in Internal Medicine and was a Medical Resident at the Cleveland Clinic Foundation.  He completed his training in medical oncology and spent a total of nine years in the NCI - Navy Medical Oncology Branch.  In 1990, he moved to the Division of Cancer Prevention and Control to start an Intramural Translation Research Group that was moved back to the Division of Clinical Sciences in 1996. Dr. Mulshine is a Fellow in the American College of Physicians, as well as a member of the American Society of Clinical Oncology, American Association of Cancer Research, International Association for the Study of Lung Cancer, and the American Federation of Clinical Research. His numerous honors include the NCI Technology Transfer Award (1996), and the National Institute of Health Director's Award in 1998.